Abstract. A work recently published experimentally demonstrates an increase in the radiobiological efficacy of clinical proton beams when a tumour is treated in
INTRODUCTION
Protontherapy represents one of the fastest growing radiotherapy modalities and one of the most attractive solutions when radiotherapy is needed, even compared to newer and advanced photon-based techniques such as intensity modulated radiation therapy (IMRT).
Protons are considered a low-LET (Linear Energy Transfer) radiation, with a clinical Relative Biological Effectiveness (RBE), assumed to be 1.1 (only ten percent bigger than gamma or x-ray radiation). Such a low biological efficiency is considered a limit especially in all those cases where radioresistant tumors must be treated, for which higher Z ions are preferred (i.e 12 C ions). For these reasons, the protontherapy community is actively investigating the possibility to increase the proton biological efficiency by the concomitant use of different drugs and/or other agents to radiosensitize the tumor.
In this paper, the possibility to take advantage of 11 B isotope as an agent able to deliver secondary particles enhancing the radiobiological effectiveness of protons triggering nuclear reactions, is discussed.
The clinical proton-Boron (p-B) approach was first proposed by Do-Kun et al. [1] . They suggested to exploit the features of the p( 11 B,α)2α fusion reaction, where low-energy (about 4 MeV) alpha particles are generated with a not negligible production cross section (around 1.7 barn) for low-energy (resonance at about 650 keV) incident protons.
The Korean group also discussed the possibility to use a 719 keV prompt-gamma, emitted in the interaction of proton with 11 B as an imaging source and potential indicator of 11 B uptake region. Giuffrida et al. [2] and Petringa et al. [3] , on the opposite, underlined that the gamma emission is not generated from the fusion process but from the elastic p( 10 B, 10 B')p' reaction (when using a mixture of 10 B and 11 B) and from the p( 11 B, 11 B')p' channel and that, in the latter case, at the clinical attainable 11 B concentration in tissues (order of 10 -5 g/cm 3 ), the peak signal would be completely masked by the non-prompt components generated as protons interact with human body natural components ( 16 O mainly).
The first experimental proof of radiobiological enhancement obtained by using the p-B reaction has been published by Cirrone et al. [4] irradiating prostate cancer cells (DU145) and non-tumorigenic breast epithelial MCF-10A cell lines along a 62 MeV clinical proton spread out Bragg peak (SOBP) at the Italian ocular protontherapy facility of INFN-LNS, Catania, Italy. Both clonogenic dose-response curves and complex type chromosomal aberration analyses clearly showed that the presence of Boron nuclei results in an increase of the radiobiological effectiveness of the proton beam. Besides the advantage of using a neutron-free nuclear fusion reaction, the relevance of this method stems from the fact that the reaction cross-section becomes significantly high at relatively low incident proton energy, i.e. around the Bragg peak region. In conventional protontherapy, the beam is typically slowed down inside the tumor (the Bragg peak region). Thus, most of the beam energy (related to the total released dose) is delivered to the tumor cells. Assuming that a given concentration of 11 B nuclei is present preferentially, but not exclusively, in the tumor volume, the incoming slow protons can trigger fusion reaction events and generate highly DNAdamaging alpha particles.
The observed radiobiological enhancement reported in [4] , even if confirmed in four experimental sessions, cannot be still explained making simple use of the reaction cross sections knowledge and/or of analytical considerations based on the classical concepts of dose, LET and RBE.
In this paper, the calculation of alpha particles along the proton SOBP in the irradiation conditions used in [4] , will be presented in detail and discussed.
The recent radiobiological experimental results on PBCT are briefly recalled in Section 2 while the estimation of the generated alpha particles along the SOBP and how these affect the LET distributions are reported in Section 3 and Section 4.
THE RADIOBIOLOGICAL EVIDENCE
In order to verify the potentiality of the 11 B(p, α)2α reaction for the enhancement of cell killing in a therapeutic protontherapy scenario, cells from the human prostate cancer line DU145 cell line have been irradiated at graded doses (0.5, 1, 2, 4 Gy) in the middle of a 62-MeV clinical SOBP.
A significant effect due to the Boron treatment (dissolved in the medium 6-8 hr prior to exposure as to give a concentration of 80 ppm) was observed throughout four experimental campaigns [4] . Based upon the measured clonogenic survival doseresponses, a Dose Modification Factor (or DMF) of 1.46 ± 0.12 was determined at the 10% survival level. This has suggested that the Boron atoms could confer a radiobiological advantage in cell killing Investigation of structural DNA damages in the form of chromosome aberrations (CAs), a wellacknowledged biomarker of high-LET radiation exposure, subsequently confirmed the presence of high-LET radiation strongly advocating their contribution to the clonogenic results.
IMAGING POTENTIALITIES OF P-11 B REACTION
The presence of Boron within or in the vicinity of the neoplastic cells could also be exploited to spatially map the biological distribution of Boron nuclei and, hence, the tumor regions where the RBE enhancement occurs [1] . In particular, the gamma emitted in the proton elastic scattering with an 11 B nucleus, generates a 718 keV prompt-gamma. The possibility to detect such gamma emission could allow 11 B localization and, consequently, identification of the proton beam interaction site.
Simulations and experimental results conducted by Petringa et al. [3] demonstrated that, if a realistic 11 B concentration is assumed, such prompt-gamma emission is impossible to be detected, being completely covered by the background gamma rays produced by proton interaction with other constituents of the human body.
In order to maintain proton-Boron therapeutic efficiency and, simultaneously, its imaging capability, the use of Boron coupled with natural Copper was proposed [5] . Copper can be easily bound to the dipyrromethene, BodiPy, a carrier molecule used for biological labelling, drug delivery and imaging. Natural Copper consists of two stable isotopes ( 63 Cu and 65 Cu) that can emit several gamma prompt peaks in the energy range between 0 to 2 MeV, mostly generated in the 63 Cu(p,p') 63 Cu elastic reactions. A combination of different prompt-gamma rays could be useful for a mapping of the dose. Specifically, the 1.3 MeV gamma line could be used, being energetically located very far from the spectral region where emission of gamma from biological components is present.
MONTE CARLO SIMULATIONS AND ANALYTICAL EVALUATIONS TO ESTIMATE THE ALPHA YIELD
Monte Carlo (MC) simulations coupled to analytical calculations were adopted to estimate the total alpha particles produced at the cell site of the experiment reported in Cirrone et al. [4] in the attempt to explain the observed radiobiological enhancement. The proton spectra at various depths in water have been reproduced using MC; these, coupled with the alpha total production cross section, allowed to derive analytically the expected alpha particle yield. The total production cross section was derived from experimental data (using the EXFOR [6] database) and TALYS [7] calculation, when experimental data were not available.
Monte Carlo simulations
Simulations were carried out using the Geant4 (GEometry ANd Tracking) toolkit [8] , version 10.04.p02 and the official Geant4 advanced example Hadrontherapy [9] . This example is able to simulate each element of the CATANA (Centro di Adroterapia ed Applicazioni Nucleari Avanzate) passive proton beam line of the INFN-LNS, where the experimental campaigns reported in [4] were performed.
The simulated geometry includes all the transport elements comprising the specific energy modulator to generate the SOBP, diagnostic elements and the water T-25 flask where cells were positioned. The latter is simulated through a box, 40x40x40 mm in dimension, divided into slices of water, 100 µm in thickness. Slices are perpendicular to the beam axis direction. The number of alpha particles was computed in the slices along the whole SOBP.
All the necessary physics processes were included in the simulations: decay physics, electromagnetic physics and physics of the hadronic (elastic and nonelastic) interactions. For hadronic processes, the Geant4 QGSP_BIC physics list was used [10] . Electromagnetic physics was included activating the G4EmStandardPhysics_opt4 physics list, able to provide high accuracy in the electrons, hadrons and ions tracking [11] .
A total of 1M proton histories have been tracked in each simulation run. 
Alpha production cross sections
Proton-Boron total production cross sections are needed for the computation of the expected number of produced alphas. TALYS-1.9 analytical code [7] was used to retrieve them due to its ability to account for all different production channels induced by protons (Figure 2 ). At low energies (below 10 MeV), the 11 B(p, α)2α channel (green curve of Figure 2 ) is the only one producing alpha particles; experimental cross sections for this channel are also available and data can be found in the EXFOR database [6] . Figure 3 shows the 11 B(p, α)2α total experimental cross section and the corresponding TALYS results when only this channel is considered. Considering that TALYS poorly describes the data below 1 MeV, we decided to adopt a combination of the two distributions as total cross section: experimental data below 4 MeV and TALYS calculations above that energy. The final resulting cross section is reported in Figure 4 . Figure 4 . total alpha production cross section adopted for alphas calculation and derived by the combination of experimental and TALYS data
Alpha estimation
A quantification of alpha particles generated at any depths (N α ) along the SOBP due to the 11 B presence was performed embedding the simulated proton spectra of Figure 1 , in the equation: (1) where σ α is the total alpha production cross section derived from the union of TALYS and experimental data (Figure 4 ), nx expressed in atoms/m 3 (nx = 3.56·10 24 atoms/m 3 corresponding to the 11 B concentration used) and d is the voxel size (100 µm).
The 11 B numerical density nx was estimated using the following equation: (2) where CB is the massic concentration of Boron (80 ppm in our case), ρtot is the total density of the target (in this case it has been taken equal to water) NA is the Avogadro constant, MB is the atomic mass of Boron and f is the fraction of 11 B with respect to the total natural Boron amount introduced into the cell culture through the BSH agent (here a fraction of 0.8 has been considered).
The final number of alpha particles is calculated by scaling the total number of proton Nx in each slide in order to obtain a dose of 2 Gy in the middle of the SOBP.
In Figure 5 the estimated number of alphas, at different depths in water along the SOBP, is reported together with the experimental depth dose distribution. 
DISCUSSION
The average Linear Energy Transfer (or LET) can be retrieved considering only the primary proton spectra along the SOBP (Figure 1 ) using the formula:
here Li is the ratio between the deposited energy by the incident proton with an energy εi and a step length li [12] .
The same definition of Equation 3 can be adopted to estimate the LET along the SOBP also including the contribution of the generated alphas nx .
The calculated LET variation, after the inclusion of the generated alphas, appears, on the one hand, to be negligible and can be shown that, in order to obtain a DMF as the one experimentally observed, a LET of the order of 4-30 keV/µm should be observed. On the other hand, these LET values can be obtained only with a number of alpha particles larger by a factor 10 2 with respect to those reported in Figure 5 . In Table 5 the proton LET, the total LET (including the generated alphas) and the corresponding DMF are reported for three different positions along the SOBP, also considering an additional alpha particle contribution which is a factor 10 2 larger with respect to the values reported in Figure 5 . The calculated DMFs values are, in this case, closer to the experimental ones. Table 1 : DMF estimation (last column) at three different depths along the SOBP; Proton dose averaged LET and Total dose averaged LET due to the contribution of alpha particles are also reported.
Conclusion
Inelastic reactions triggered by energetic protons as they slow down across a clinical SOBP interacting with Boron nuclei seem to produce an enhancement of proton radiobiological effectiveness. These results, even if experimentally well corroborated by repeated experimental campaigns [4] , seem to fall short of an immediate justification by estimations merely based on analytical and Monte Carlo evaluations of classical dosimetric quantities such as integral dose, LET and RBE.
The total number of alpha particles generated, and estimated on the basis of the well-known total production cross section of the p-B reaction, does not explain the experimental results in terms of an average LET increase and, hence, with a corresponding RBE enhancement. On the opposite, if classical radiobiological models are applied, in order to reach the observed DMF values, one would require a number of alpha particles larger by a factor 10 3 with respect to the calculated yield.
